GU Ventures
Since 1995, GU Ventures has supported projects and companies spawned by the University of Gothenburg. The company is wholly owned by the Swedish state and managed since 1998 by the University of Gothenburg. They are located at Erik Dahlbergsgatan at Vasaplatsen in Gothenburg on the same street as the University of Gothenburg Research and Innovation Office, Företagarna and Nyföretagarcentrumand, within walking distance to the University of Gothenburg's main building and several faculties. In close collaboration with the Research and Innovation Office at GU, Innovationskontor Väst and the Gothenburg innovation system with partners such as Encubator, Chalmers Innovation, Framtidens Företag and Sahlgrenska Science Park, they contribute to the renewal of industry through commercialization of research and expertise. All business ideas must have commercial viability and solve a problem for a customer. The companies shall strive to become profitable and successful by satisfying a market need. The aim is to create successful businesses to generate good knowledge- and capital repayment to the University of Gothenburg. Furthermore, they intend to increase growth in the region and contribute to the utilization of research for a better life and society with new products and services.
Thioredoxin Systems is focused on developing an innovative antibiotic regimen specifically aimed at treating complicated urinary tract infections. The company utilizes a patented combination of ebselen and silver, which is effective against a wide range of multi-drug resistant bacteria. This technology serves multiple purposes, functioning as an antiseptic and antibacterial agent in food production, as well as a medicinal product. By employing this approach, Thioredoxin Systems aims to assist medical professionals in slowing the progression of multi-drug resistance and preventing the development of resistance to antibiotics.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Profundus Imaging is developed a new fundus camera that could be used to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease. The camera is built on so-called Adaptive Optics, a technology that is normally used in terrestrial space telescopes and was developed due to a need for improved resolution in retinal imaging and offers 7-10 times higher resolution than conventional instruments over a considerably larger imaging area than competing concepts.
OnDosis is a company focused on transforming medication delivery through its proprietary technology, which allows for flexible and individualized dosing of oral medicines formulated as micro units. The company aims to enhance disease management, support patient adherence, and improve convenience for individuals with conditions such as ADHD, pain management, and organ transplant immunosuppression. By offering improved dosing options, OnDosis seeks to address significant healthcare burdens and ultimately enhance patient outcomes. Founded in 2017 and headquartered in Gothenburg, Sweden, OnDosis emerged from research initiated at AstraZeneca and is supported by strategic partnerships in formulation, device development, regulatory affairs, and business development. The company's innovative dosage manager integrates digital technologies with conventional drug treatments, positioning it to make a meaningful impact in personalized medicine.
Mimbly is a company focused on sustainability through innovative water-saving and microplastic-capturing solutions. It manufactures a system designed for laundry applications that recycles water in washing processes. This system connects to a washing machine via a water intake valve, where it tracks, analyzes, and purifies water during each cycle, allowing for its reuse. Mimbly's technology enables professional laundry facilities to adopt more sustainable practices, significantly conserving water, reducing microplastic pollution, and lowering CO2 emissions.
Recycla is Sweden's largest recycling platform, providing people and businesses with cost-effective solutions to all their recycling needs.
Cereno Scientific AB is focused on developing innovative treatments for patients at increased risk of blood clotting, leveraging its patented research on epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug designed to prevent venous thrombosis and stroke in individuals with atrial fibrillation. In addition to its work on cardiovascular conditions, Cereno Scientific is exploring the therapeutic potential of its technologies for rare diseases associated with pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system. By normalizing the body’s defense mechanisms against blood clots, Cereno aims to address significant complications in cardiovascular health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.